Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 22.68 as of Sunday, July 26, 2026.
Forward PE Ratio (22.68) = Close Price ($568.26) / Consensus Forward EPS ($25.05)
FORWARD PE RATIO
22.68
SECTOR MEDIAN · HEALTHCARE
18.38
median of 68 covered companies
CURRENT VS SECTOR MEDIAN
+23.36%
vs the sector median at left
Thermo Fisher Scientific Inc.
Market Cap
$211.18B
Forward PE Ratio
22.68
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Thermo Fisher Scientific Inc. (TMO) | $211.18B | 22.68 |
| Novo Nordisk A/S (NVO)vs › | $216.72B | N/A |
| Amgen Inc. (AMGN)vs › | $202.95B | 16.83 |
| Abbott Laboratories (ABT)vs › | $179.58B | 18.72 |
| Gilead Sciences, Inc. (GILD)vs › | $160.55B | N/A |
| Pfizer Inc. (PFE)vs › | $139.86B | 8.34 |
| CVS Health Corp. (CVS)vs › | $137.47B | 14.46 |
| Danaher Corporation (DHR)vs › | $134.62B | 22.57 |
| AstraZeneca PLC (AZN)vs › | $131.16B | 16.54 |
| Bristol-Myers Squibb Company (BMY)vs › | $126.79B | 9.79 |
Trailing P/E
30.6
reported TTM EPS
Forward P/E
22.7
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $25.05 implies +34.7% EPS growth vs the reported trailing $18.59.
At today's $568.26 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $25.05 | $24.72 – $25.30 | 13 | 22.7x |
| 2027-12-31 | $27.38 | $26.19 – $29.01 | 15 | 20.8x |
| 2028-12-31 | $30.17 | $27.17 – $32.46 | 5 | 18.8x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
